Bristol Myers director awarded deferred share units
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 577.082 | $60.65 | $35K |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Key Figures
Key Terms
1987 Deferred Compensation Plan for Non-Employee Directors financial
dividends reinvested financial
settleable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BMY director Phyllis R. Yale report?
AI-generated analysis. How Rhea-AI works. Not financial advice.